Literature DB >> 26160963

Is thoracoscopic patent ductus arteriosus closure superior to conventional surgery?

Tomasz Stankowski1, Sleiman Sebastian Aboul-Hassan1, Jakub Marczak2, Romuald Cichon3.   

Abstract

A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether thoracoscopic patent ductus arteriosus (PDA) closure is superior to conventional surgery. Altogether 821 papers were found using the reported search, 11 of which represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. Eleven studies included in the analysis consisted of two prospective and three retrospective, non-randomized studies and six case series. Four included studies focused only on preterm infants, three studies enrolled neonates and the other four analysed all age groups from neonates to older children or young adults. There were no differences in mortality between video-assisted thoracoscopic surgery (VATS) and conventional surgery. Two studies suggested that VATS offers shorter operative times. Two papers observed shorter hospital stay, although the other two noted no significant difference. A large prospective trial found VATS to be associated with a lower number of postoperative complications in neonates and infants, whereas other studies suggested no significant differences in short-term postoperative complications. There is little evidence to suggest better musculoskeletal status and cosmesis in neonates following VATS. Conversion from thoracoscopy to thoracotomy described in six papers was seldom and it did not lead to any additional complications. All observational studies confirmed that both techniques are free from major adverse cardiovascular complications and these two techniques can be safely used in all patients qualified for surgical PDA closure. Two studies compared cost-effectiveness between the two techniques; one of them described VATS as significantly more cost-efficient, whereas the other study observed no difference. However, it should be noted that data were provided from different countries and time periods. The results presented suggest that there are no significant differences in early clinical outcomes between VATS and thoracotomy in all age groups. However, where differences have been shown, such as pain, postoperative complications, length of hospital and ICU stay and cost, these favour the VATS approach.
© The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Patent ductus arteriosus; Patent ductus arteriosus ligation; Thoracotomy; Video-assisted thoracoscopy

Mesh:

Year:  2015        PMID: 26160963     DOI: 10.1093/icvts/ivv185

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  3 in total

1.  Iatrogenic obstruction of the aorta - a sequence of delayed, fatal complications after 'off-label' interventional persistent ductus arteriosus closure.

Authors:  Ireneusz Haponiuk; Konrad Paczkowski; Maciej Chojnicki; Radosław Jaworski
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2016-02-01       Impact factor: 1.195

2.  Conversion to thoracotomy of video-assisted thoracoscopic closure of patent ductus arteriosus.

Authors:  Tomasz Stankowski; Sleiman Sebastian Aboul-Hassan; Dirk Fritzsche; Marcin Misterski; Jakub Marczak; Anna Szymańska; Katarzyna Wijatkowska; Cyprian Augustyn; Romuald Cichoń; Bartłomiej Perek
Journal:  Kardiochir Torakochirurgia Pol       Date:  2018-06-25

3.  Descriptive review of patent ductus arteriosus ligation by video-assisted thoracoscopy in pediatric population: 7-year experience.

Authors:  Tomasz Stankowski; Sleiman Sebastian Aboul-Hassan; Farzaneh Seifi-Zinab; Dirk Fritzsche; Marcin Misterski; Ivan Sazdovski; Jakub Marczak; Anna Szymańska; Lukasz Szarpak; Kurt Ruetzler; Sanchit Ahuja; Bartłomiej Perek
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.